
THE NUMBER 14%.That is how far below the bottom of its range vVARDIS priced its IPO. The Swiss dental company sold about 9.7 million shares at $18. It had marketed the deal at $21 to $24 a share. On Thursday, it had already cut the share count once. Apollo Global Management (APO) funds hold a minority stake bought earlier this year. Whether any holder is selling has not been disclosed. The shares start trading in New York today. Here, public buyers set the price, and the price gave way.
THE SETUP - Nvidia (NVDA) closed down 4.3% Thursday, the day it announced Jensen Huang's resignation. Before dawn, its shares were quoted almost 3% higher. Several brokerages cut the stock Thursday. Huang agreed to testify behind closed doors, House Foreign Affairs Committee Chairman Brian Mast said. Nvidia reports Tuesday.
- The 10-year Treasury yield was near 5.1%. Two-year yields rose 40 basis points in a week. October producer prices arrive at 8:30, after this email.
- Nasdaq-100 futures were flat.
PMD Signal Tracker 
FROM OUR PARTNERS 
But unlike most people, Elon’s wealth doesn’t come from a salary or a pension… It comes from something completely different… And today, legendary investor James Altucher reveals how YOU can follow Elon’s wealth-building blueprint… In a brand-new FREE report called “Elon’s Trillion Dollar Money Map”. Click here to learn how to claim your FREE copy of this essential report NOW.
IN FOCUS OpenAI Raised About Half of What It Sought, CNBC Reported, at a Price It Had Already CutOpenAI has raised $15 billion, CNBC reported Thursday, citing unnamed people. The report put the valuation at $1.25 trillion. OpenAI first sought as much as $30 billion at a $1.4 trillion valuation, CNBC said. The round has not formally closed. That is expected within the next couple of weeks. The company has not issued a release, and the investors have not been named. When a late-stage round falls short, the usual fix is a lower price. OpenAI made that cut in October, to $1.25 trillion. Since then, as reported, the change has gone to size. The price held, and the money came in at about half the ask. The raise was framed as a bridge to a listing in 2027, according to the report. The stakes go beyond OpenAI. Late-stage AI marks lean on a few headline rounds. A round that holds its price after one cut still supports the marks beneath it, even when the money falls short. The other read is that demand for the full $30 billion was not there, even at the lower price. The Price Held After One Cut. Did the Buyers Thin? For investors holding private AI stakes, this round is the new reference mark. It has held since October's cut. Funds value those stakes off a few rounds like this one. A price that holds can support their marks. But half the money at that price also suggests fewer buyers would pay it. The formal close, the investors' names and the terms of any listing would show which read is right.
SIGNALS IN MOTION SIGNAL 1: Ares Found Its Investors a Way Out Before the Borrowers Repay, Bloomberg Reported.Ares (ARES) raised about €3.3 billion for a continuation fund, Bloomberg reported. It cited people familiar with the matter. Coller EQT led the fund, which takes 24 loans from an Ares credit fund raised in 2018. Neither firm has issued a release. A direct lending fund pays its investors as its loans are repaid. Those loans usually get repaid when buyout firms sell or refinance the companies. With few sales, few loans are repaid. So a new fund buys the loans, and the old fund's investors can take cash or roll over. WHAT RESOLVES THIS For investors in older private credit funds, this offers cash without waiting for exits. The catch is the price paid for the loans, which sets what those investors actually get back. That price is not public, and neither is the loans' quality. If either comes out, it will show whether this fixes slow exits or just moves a problem. SIGNAL 2: Braskem's Creditors Converged on a $4 Billion Plan. Its Owners Want About $5 Billion, Valor Reported.Braskem's board reviewed three creditor proposals Thursday without reaching agreement, Valor reported, citing sources. Bondholders, banks and local debt holders all landed near $4 billion in total. The company, Petrobras and controlling holder IG4 want about $5 billion. The gap is mostly about how much debt turns into shares. Petrobras expects $3.6 billion of debt to convert, Folha reported. Creditors' three plans would convert $2.5 billion to $2.7 billion, Valor reported. More conversion cuts the debt, and it hands creditors more of the company. Braskem did not make payments due Nov. 9 on one local bond issue, citing the stay that comes with its out-of-court process. WHAT RESOLVES THIS For bondholders, the fight is over who owns Braskem afterward, not just how much cash goes in. Money is at stake because a failed out-of-court plan usually moves to a court process, which is slower and costs more. The window closes Nov. 22 or 23, and the private deadline is expected to be extended again. A narrower gap from either side would show who gave way.
WHAT MOST WILL MISS - Nakamoto (NAKA) owes Kraken 165 million tether. The loan is secured by its bitcoin, and it is more than the company's stock-market value. Kraken agreed to push a payment due Dec. 4 out by a year. That leaves no principal due this year. Nakamoto's pledged coins cover about 127% of the loan at current prices.
- Bitcoin fell to about $68,000 overnight, its lowest since Aug. 20. Strategy (MSTR) paid about $75,500 a coin on average. Friday's early price is about 8% below that. Its funding is mostly unsecured convertibles and preferred stock. A lower price does not trigger a collateral call.
THE CROSSOVER Private Market Trends Driving Public Market MovesOpenAI Held Its Lower Price. vVARDIS Could Not. OpenAI held the $1.25 trillion price it set in October, down from $1.4 trillion, and raised about half the money, CNBC reported. Ares moved old loans into a new fund rather than wait for repayment, Bloomberg reported. Nakamoto got another year on part of its loan, and Braskem's talks look set to run past another deadline. In each case this month, size or time gave way. No new price cut was disclosed, though the price Ares's new fund paid is not public. vVARDIS tried a smaller deal first, and public buyers still priced it 14% under its range. Our read is that private marks can hold until a sale or listing forces a price. A listing well below its last private round would test that. On the calendar... When | Event | Fri., Nov. 13 | Producer prices; vVARDIS begins trading | Mon., Nov. 16 | vVARDIS offering expected to close | Tue., Nov. 17 | Nvidia reports; retail sales | Wed., Nov. 18 | Fed minutes | Tue.-Wed., Dec. 8-9 | Fed meeting |
Big Pharma Stopped Watching AI Drug Discovery. It Started Paying.Sanofi has paid one AI biotech $144 million in upfront and milestone payments. Eli Lilly invested $40 million in another. Bristol Myers Squibb is putting a third company's AI co-scientist to work inside its own research organization. The industry's biggest drugmakers used to watch this technology from the sidelines. Now they're customers. We profiled the 5 companies leading AI drug development in a new FREE Special Report: AI Moves Into the Biotech Lab. We'll text it straight to your phone. Get the Free Report by Text → |